New hope for rare kidney disease? first human trial of CPV-104 begins
Disease control
Recruiting now
This study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receivin…
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC